James Bullington

Title: James Bullington: Innovator in Melanocortin Receptor Compounds

Introduction

James Bullington is a notable inventor based in Hamilton Square, NJ (US). He has made significant contributions to the field of pharmacology, particularly in the development of compounds that target melanocortin receptors. His work is essential for advancing treatments for various diseases and disorders.

Latest Patents

James Bullington holds a patent for "Orally active melanocortin receptor-4 compounds." This patent describes a compound of the formula where R, R, R, R, R, R, and R are defined in the specification and claims. The patent also covers enantiomers, stereoisomers, or diastereoisomers of the compound, as well as pharmaceutically acceptable salts. The use of these compounds is aimed at treating diseases, disorders, syndromes, and conditions that respond to the modulation of a melanocortin receptor.

Career Highlights

James Bullington is associated with Palatin Technologies Incorporated, a company that focuses on innovative therapeutic solutions. His work at Palatin Technologies has been instrumental in advancing research and development in the field of melanocortin receptor modulation.

Collaborations

James has collaborated with notable colleagues, including Axel Metzger and John H Dodd. These collaborations have contributed to the success of his research and the development of new therapeutic compounds.

Conclusion

James Bullington is a prominent inventor whose work on melanocortin receptor compounds has the potential to impact the treatment of various medical conditions. His contributions to the field are significant and continue to pave the way for future innovations.